Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc.

Stock
Stock
Ticker: CAI
CAI

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Caris Life Sciences, Inc. is $6.88B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Caris Life Sciences, Inc. is 65.38. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Caris Life Sciences, Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.372. EPS indicates the company's profitability on a per-share basis.
Currently, 14 analysts cover Caris Life Sciences, Inc.'s stock, with a consensus target price of $27.38. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Caris Life Sciences, Inc. reported a revenue of $989.61M.
Caris Life Sciences, Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $174.02M. EBITDA measures the company's overall financial performance.
Caris Life Sciences, Inc. has a free cash flow of $116.25M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Caris Life Sciences, Inc. employs approximately 1,846 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Caris Life Sciences, Inc. is 126.33M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$6.88B
EPS (TTM) 
$0.372
Free Float 
126.33M
P/E ratio (TTM) 
65.38
Revenue (TTM) 
$989.61M
EBITDA (TTM) 
$174.02M
Free Cashflow (TTM) 
$116.25M

Pricing

1D span
$24.00$24.72
52W span
$14.19$34.35

Analyst Ratings

The price target is $27.38 and the stock is covered by 14 analysts.

Buy

10

Hold

4

Sell

0

Information

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

Employees
1,846
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
CAI

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation